The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

In Brief

The Community Oncology Alliance appoints new officers

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

THE COMMUNITY ONCOLOGY ALLIANCE appointed new officers. Bruce Gould, of Northwest Georgia Oncology Centers in Marietta, Ga., was named president of COA.

Jeff Vacirca, of North Shore Hematology Oncology Associates in East Setauket, N.Y., was named vice-president; Michael Diaz, of Florida Cancer Specialists and Research Institute in Tampa, Fla., was named secretary; and Ricky Newton, of Cancer Specialists of Tidewater in Chesapeake, Va, was named treasurer.

The COA’s immediate past president is Mark Thompson, of The Zangmeister Center in Columbus, Ohio, who will continue to serve as chairman of the COA Payment Reform Task Force and legislative liaison on congressional matters. Past President David Eagle, of Lake Norman Hematology Oncology in Charlotte, N.C., will assume the position of chairman of the Oncology Medical Home Steering Committee.

Table of Contents

YOU MAY BE INTERESTED IN

News Analysis

GRAIL presses on with Galleri test despite missed primary endpoint in pivotal study
Where GRAIL sees signals of benefit in the subgroups, screening experts see signs of overdiagnosis

If you listen to GRAIL executives discuss the results of the long-awaited trial of the company’s multicancer detection test, you might be led to conclude that the company’s pivotal NHS-Galleri study had an overwhelmingly positive result.
By Jacquelyn Cobb and Sara Willa Ernst
Conversation with The Cancer Letter

GRAIL’s Megan Hall: “I think we can be confident that there is clinical benefit to implementing this technology. And I think that’s really hard to argue with.”
Mainstream epidemiologists beg to differ

Undeterred by the negative topline result of its pivotal trial of Galleri, a multicancer detection test, the test’s sponsor, GRAIL, said it’s forging ahead with its plan to get FDA approval and reimbursement from CMS and private insurers.
By Jacquelyn Cobb and Sara Willa Ernst
Conversation with The Cancer Letter

NCI’s Philip Castle on NHS-Galleri results: “I’m sorry that it didn’t work, but it keeps the national conversation going.”
Castle is “disappointed” by Galleri results but not discouraged by implications for MCDs

Philip E. Castle, director of the NCI Division of Cancer Prevention, said he was disappointed to hear that GRAIL’s NHS-Galleri trial did not meet its primary endpoint of reduction in late-stage cancers.
By Jacquelyn Cobb and Sara Willa Ernst
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account